The tissue section shows clear positive staining, but the Western blot has no band at the expected molecular weight. It is tempting to decide that one result must be wrong. In practice, the two findings can coexist: IHC and Western blot examine proteins in different contexts, use different sample preparation steps, and provide different kinds of evidence.

An IHC-positive result does not automatically mean that the same target will be detectable by Western blot. Nor does a negative Western blot, by itself, prove that the IHC staining is nonspecific. The key question is what each experiment actually demonstrates—and what remains untested.

In This Article

  1. Why Can IHC Be Positive While Western Blot Is Negative?
  2. Six Reasons for IHC-Positive, Western-Blot-Negative Results
  3. How Epitope Accessibility Differs Between IHC and Western Blot
  4. How to Investigate Conflicting Results
  5. How to Evaluate Whether the IHC Signal Is Target-Specific
  6. How to Interpret the Results Without Overstating the Evidence
  7. Conclusion

1. Why Can IHC Be Positive While Western Blot Is Negative?

IHC shows where antibody-associated signal appears within tissue architecture. It can reveal staining in a particular cell population, anatomical region, or subcellular location. Western blot, by contrast, detects immunoreactive proteins after extraction and electrophoretic separation; it does not retain the spatial information visible in a tissue section [1,2].

For an overview of the method’s stages, see the Western blotting principle and protocol guide.

This difference matters when a target is present in only a small subset of cells. A distinct IHC signal in those cells may be less apparent in a bulk lysate that also contains protein from surrounding cells, stroma, or other tissue components. If the target is below the detection capability of the Western blot conditions, a band may not be visible even though staining can be seen in selected tissue areas. This is a plausible explanation to test, not a conclusion that can be drawn from the discordant results alone [1,2].

The samples may also differ. IHC is often performed on fixed, paraffin-embedded tissue, while Western blot uses material prepared for protein extraction. If the assays used different tissue regions, blocks, collection times, or processing conditions, the results may not be directly comparable [1,3,4]. Confirm sample comparability before attributing the discrepancy to the antibody.

For practical guidance on tissue-section workflows, see the IHC protocol guide.

2. Six Reasons for IHC-Positive, Western-Blot-Negative Results

Possible explanation Why it may matter Evidence to check
Low target abundance in the lysate A localized IHC signal may be less apparent in a bulk lysate Tissue region, cell composition, protein load, WB detection capability
Different sample composition The assays may use different tissue regions or specimens Whether the samples are biologically comparable
Incomplete protein extraction The target may not be recovered efficiently in the fraction analyzed Extraction method and target’s biochemical properties
Different epitope accessibility Fixation and antigen retrieval affect IHC; WB preparation changes the antigen context Antibody epitope and conditions used in both assays
Application-dependent antibody performance Performance in one assay does not establish performance in another Independent validation data for IHC and WB
IHC signal may not be target-specific Staining in an expected location does not alone prove target identity Appropriate controls and independent evidence

These are explanations to investigate, not diagnoses that can be made from the pattern alone. IHC validation guidance recommends a weight-of-evidence approach: controls, known-expression samples, Western blotting, and other methods can each contribute evidence, but each has limitations [1,2].

Boster’s overview of application-specific antibody validation across WB, IHC, IF, and flow explains why validation evidence does not automatically transfer between methods.

3. How Epitope Accessibility Differs Between IHC and Western Blot

The antibody does not encounter the target protein in the same state in both methods. In IHC, fixation and tissue processing can modify proteins and alter epitope accessibility. Antigen retrieval may restore recognition for some epitopes, but its effect depends on the target, antibody, fixative, and retrieval conditions [1,3,4].

For a practical explanation of fixation-related epitope masking, see IHC antigen retrieval methods.

For Western blot, proteins are commonly extracted and treated with detergents and, often, reducing or denaturing agents before electrophoresis. These steps help separate proteins by apparent molecular weight but can disrupt higher-order protein structure. An antibody that recognizes an epitope accessible in processed tissue may not recognize the protein efficiently after the preparation used for WB. Conversely, an antibody that works well with denatured protein may perform poorly in IHC if its epitope is inaccessible in the tissue.

This does not mean IHC always detects native conformations or Western blot always detects only linear epitopes. The outcome depends on the antibody, epitope, antigen processing, and assay protocol. The relevant point is that performance in one application cannot be assumed to predict performance in another [1,2,3].

4. How to Investigate Conflicting Results

The most efficient approach is to check the evidence in an order that helps separate a workflow problem from a sample-specific or antibody-specific explanation.

First, confirm that the samples are comparable

Check whether IHC and WB used the same tissue type and comparable regions, and whether collection, storage, and processing differed. A small tissue section enriched for target-positive cells may not represent the composition of a larger lysate. If the samples are not matched, biological differences may explain part of the discrepancy before technical issues are considered.

The IHC principle guide provides additional background on tissue staining and antigen detection.

Next, check whether each method worked as intended

For IHC, review the expected staining distribution and the positive and negative controls. A no-primary-antibody control can reveal some background from the detection system, but it does not by itself establish target specificity. For WB, check whether the positive control produced the expected result. If it also fails, review the WB workflow, reagents, transfer, and detection conditions before interpreting the tissue sample. If the control works but the tissue lysate does not, focus on sample composition, target abundance, extraction, and assay-specific recognition.

Boster’s Western blot troubleshooting guide covers weak or absent bands and other common blot problems.

For a more detailed discussion of positive, negative, and no-primary controls, see 6 essential IHC controls.

Then, choose a test that distinguishes the remaining explanations

If IHC specificity is uncertain, genetic controls such as knockout or knockdown material, where available, or an independent antibody recognizing a different epitope can provide complementary evidence [1,2]. If extraction is the leading concern, assess whether the extraction method suits the target and the fraction being analyzed. If the expected band is uncertain, review documented isoforms, processing products, and modifications before assigning identity based on molecular weight alone.

The Western blot protocol outlines the separation, transfer, and detection workflow.

Review the Western blot sample preparation guide for factors that can affect protein recovery and lysate quality.

The aim is not to run every possible experiment. It is to choose the next control or method that most directly tests the explanation still in question.

5. How to Evaluate Whether the IHC Signal Is Target-Specific

Positive staining in the expected location supports the possibility that the target is present, but localization alone does not prove that every stained structure represents the intended protein. IHC specificity is best assessed by combining evidence rather than relying on a visually convincing pattern or a single control [1].

A suitable positive control shows that the staining procedure can detect the target under the tested conditions. Negative tissue or genetic controls can help assess whether the signal depends on target expression. An independent antibody directed against another epitope may add support if it produces a biologically consistent pattern. Each approach has limitations: an antibody may cross-react with related proteins, and an unsuitable control may fail to expose a specificity problem.

Western blot can add biochemical evidence because it separates immunoreactive proteins by apparent molecular weight. A band at the expected position may support target recognition, but band position alone is not definitive proof of identity. Conversely, failure to detect a band does not automatically invalidate IHC: the target may be poorly extracted, below the WB detection capability, or recognized differently under denaturing conditions [1,2].

For additional context on protein loading and the detection range, see How much protein should you load for Western blot?.

6. How to Interpret the Results Without Overstating the Evidence

Finding What the evidence supports What it does not prove
IHC positive; WB conditions not verified The IHC signal is observed, but the WB result remains unresolved That the target is absent or the antibody is nonspecific
IHC positive; specificity controls are limited The staining pattern needs further validation That all staining is target-specific
WB positive at expected molecular weight with suitable controls Adds biochemical evidence consistent with target recognition That IHC staining is automatically specific in every tissue
Results remain discordant after basic checks More evidence is needed to distinguish biological and technical explanations That one method must be correct because it matches expectations

The goal is not to choose IHC over Western blot or vice versa. It is to define what each result supports and resolve the most important uncertainty with an appropriate control or complementary method. Confidence comes from converging evidence, with each result interpreted in the context of the assay used [1,2].

Conclusion

When IHC is positive but Western blot is negative, neither result should be dismissed automatically. Tissue localization, sample composition, protein extraction, epitope accessibility, and application-specific antibody performance can all affect the comparison. Confirm that the samples and controls are comparable, then test the most plausible explanation rather than changing several conditions at once.

A positive IHC pattern is not, by itself, definitive proof of target specificity, and a negative Western blot is not proof that the target is absent. The most defensible conclusion comes from controls and complementary evidence that directly address the unresolved question.

References

[1] Webster JD, Solon M, Gibson-Corley KN. Validating Immunohistochemistry Assay Specificity in Investigative Studies: Considerations for a Weight of Evidence Approach. Veterinary Pathology. 2021;58(5):829–840. doi:10.1177/0300985820960132. PubMed

[2] Pillai-Kastoori L, Heaton S, Shiflett SD, et al. Antibody validation for Western blot: By the user, for the user. Journal of Biological Chemistry. 2020;295(4):926–939. doi:10.1074/jbc.RA119.010472. PubMed

[3] Stumptner C, Pabst D, Loibner M, Viertler C, Zatloukal K. The impact of crosslinking and non-crosslinking fixatives on antigen retrieval and immunohistochemistry. New Biotechnology. 2019;52:69–83. doi:10.1016/j.nbt.2019.05.003. Journal article

[4] Rodig SJ. Preparing Paraffin Tissue Sections for Staining. Cold Spring Harbor Protocols. 2021;2021(3):pdb.prot099663. doi:10.1101/pdb.prot099663. PubMed